Hypercholesterolemia, cardiovascular risk and treatment in the elderly;Ipercolesterolemia, rischio cardiovascolare e terapia ipocolesterolemizzante nell'anziano

Recenti Progressi in Medicina

Volumn 93, Issue 4, 2002, Pages 264-272

  Cicconetti, Paolo ^a,b   Ciotti, Veronica ^a   Tafaro, Laura ^a   Riolo, Noemi ^a   Marigliano, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Hypercholesterolemia; Old elderly; Primary and secondary prevention; Statins; Young elderly

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AGED; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; HYPERCHOLESTEROLEMIA; LIFESPAN; MORTALITY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

AGE FACTORS; AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0036210874     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Ipertensione arteriosa in età senile: Fattore di rischio e fattori di rischio
2. Fattori di rischio cardiovascolare e diabete
3. Smoking and mortality among older men and women in three communities
4. Cholesterol in the elderly. Is it important?
5. Plasma lipid distributions in selected North American populations. The Lipid Research Clinics Program Prevalence study
6. Lipoprotein lipids in older people. Results from the Cardiovascular Health study
7. Abbassare la colesterolemia per ridurre la cardiopatia coronarica
8. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older
9. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 Year follow up in Whitehall study
10. Evaluation of cardiovascular risk in the elderly: The Framingham study
11. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
12. Is it advantageous to lower cholesterol in the elderly hypertensive?
13. Prevalence of chronic diseases in older italians: Comparing self-reported and clinical diagnosis
14. High blood cholesterol in elderly men and the excess risk for CHD
15. Treating high blood cholesterol in the older patient
16. Cardiovascular risk factors in the elderly
17. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?
18. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years
19. Total cholesterol and risk of mortality in the oldest old
20. HDL Cholesterol predicts coronary heart disease mortality in older persons
21. Cholesterol levels and mortality in a cohort of old-old
22. Fattori di rischio e patologie cardiovascolari nei centenari
23. Report of the Conference on Low Blood Cholesterol: Mortality associations
24. "Naturally occurring" low blood cholesterol and excess mortality
25. Ipertensione arteriosa nei molto anziani. Problemi di trattamento
26. Cholesterol, diastolic blood pressure, and stroke. 13000 Strokes in 450 000 people in 45 prospective cohorts
27. Risk factors for ischemic stroke. Dubbo study of the elderly
28. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention trial
29. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S)
30. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S)
31. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial
32. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
33. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
34. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial
35. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
36. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events
37. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS Airforce/Texas Coronary Atherosclerosis Prevention Study
38. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
39. Effects of fats and fatty acids on blood lipids in humans: An overview
40. Physical exercise in the elderly
41. Cholesterol lowering in the elderly population
42. Executive summary of the third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
43. Prevention des maladies cardiovasculaires chez le sujet agé hypercholestérolémique
44. Cholesterol and coronary heart disease in older adults. No easy answers
45. AHA scientific statement. Primary prevention of coronary heart disease. Guidance from Framingham
46. Linee guida nel trattamento delle dislipidemie e degli altri fattori di rischio di cardiopatia ischemica
47. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
48. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study
49. Risk factors that attenuate the female coronary disease advantage
50. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials
51. Statine: Analogie e differenze negli aspetti farmacologici, clinici e di laboratorio
52. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercolesterolemia (the CURVES study)
53. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
54. Pleiotropic effects of statins and their clinical significance
55. Non- lipid-related effects statins (Trends in Clinical Practice)
56. Effect of simvastatin on coronary atheroma: The Multicentric Anti-Atheroma Study (MAAS)
57. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
58. The evolving role of statins in the management of atherosclerosis
59. Le promesse delle statine
60. Le reazioni avverse da farmaci nell'anziano
61. Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: Is the interaction predictable?
62. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercolesterolemia
63. Rhabdomyolysis due to cerivastatin monotherapy
64. Effect of statins on risk of coronary disease. A meta-analysis of randomised controlled trials
65. Cholesterol lowering in the elderly. Results of the cholesterol reduction in Seniors Program (CRISP) Pilot study
66. Terapia farmacologica nell'anziano
67. The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
68. MRC/BHF Heart Protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience